189 related articles for article (PubMed ID: 12208409)
1. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
4. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
[TBL] [Abstract][Full Text] [Related]
5. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
Ferrario CM; Smith RD; Brosnihan B; Chappell MC; Campese VM; Vesterqvist O; Liao WC; Ruddy MC; Grim CE
Am J Hypertens; 2002 Jun; 15(6):557-64. PubMed ID: 12074359
[TBL] [Abstract][Full Text] [Related]
6. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
McClean DR; Ikram H; Garlick AH; Richards AM; Nicholls MG; Crozier IG
J Am Coll Cardiol; 2000 Aug; 36(2):479-86. PubMed ID: 10933361
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
8. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
Nathisuwan S; Talbert RL
Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
[TBL] [Abstract][Full Text] [Related]
9. Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Klapholz M; Thomas I; Eng C; Iteld BJ; Ponce GA; Niederman AL; Bilsker M; Heywood JT; Synhorst D
Am J Cardiol; 2001 Sep; 88(6):657-61. PubMed ID: 11564390
[TBL] [Abstract][Full Text] [Related]
10. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
Campese VM; Lasseter KC; Ferrario CM; Smith WB; Ruddy MC; Grim CE; Smith RD; Vargas R; Habashy MF; Vesterqvist O; Delaney CL; Liao WC
Hypertension; 2001 Dec; 38(6):1342-8. PubMed ID: 11751715
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
[TBL] [Abstract][Full Text] [Related]
13. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
[TBL] [Abstract][Full Text] [Related]
15. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
McClean DR; Ikram H; Garlick AH; Crozier IG
Am J Cardiol; 2001 Mar; 87(5):565-9. PubMed ID: 11230840
[TBL] [Abstract][Full Text] [Related]
16. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure.
Bergler-Klein J; Pacher R; Berger R; Bojic A; Stanek B
J Heart Lung Transplant; 2004 Jan; 23(1):20-7. PubMed ID: 14734123
[TBL] [Abstract][Full Text] [Related]
17. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
[TBL] [Abstract][Full Text] [Related]
18. [Heart failure and vasopeptidase inhibitors].
Bareiss P; Ohlmann P; Roul G
Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.
Kostis JB; Klapholz M; Delaney C; Vesterqvist O; Cohen M; Manning JA; Jemal M; Kollia GD; Liao WC
J Clin Pharmacol; 2001 Dec; 41(12):1280-90. PubMed ID: 11762555
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
